[1]张彦平,刘蒙蒙,展新荣.地西他滨联合三氧化二砷治疗老年急性髓系白血病的疗效及安全性[J].新乡医学院学报,2019,36(12):1163-1166.[doi:10.7683/xxyxyxb.2019.12.015]
　ZHANG Yan-ping,LIU Meng-meng,ZHAN Xin-rong.Evaluation of the efficacy and safety of decitabine combined with arsenic trioxide in the treatment of senile acute myeloid leukemia[J].Journal of Xinxiang Medical University,2019,36(12):1163-1166.[doi:10.7683/xxyxyxb.2019.12.015]
点击复制

地西他滨联合三氧化二砷治疗老年急性髓系白血病的疗效及安全性
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
36
期数:
2019年12
页码:
1163-1166
栏目:
临床研究
出版日期:
2019-12-12

文章信息/Info

Title:
Evaluation of the efficacy and safety of decitabine combined with arsenic trioxide in the treatment of senile acute myeloid leukemia
作者:
张彦平; 刘蒙蒙; 展新荣
（新乡市中心医院血液内科，河南　新乡　453000）
Author(s):
ZHANG Yan-ping; LIU Meng-meng; ZHAN Xin-rong
(Department of Hematology，Xinxiang Central Hospital，Xinxiang 453000，Henan Province，China)
关键词:
急性髓系白血病; 地西他滨; 三氧化二砷; 高三尖杉酯碱; 盐酸阿糖胞苷
Keywords:
acute myeloid leukemia;  decitabine;  arsenic trioxide;  homoharringtonine;  cytarabine hydrochloride
分类号:
R733.71
DOI:
10.7683/xxyxyxb.2019.12.015
文献标志码:
A
摘要:
目的　探讨地西他滨联合三氧化二砷治疗老年急性髓系白血病（非急性早幼粒细胞白血病）的临床效果及安全性。方法　选择 2016年2月至2018年10月新乡市中心医院收治的54例老年急性髓系白血病患者为研究对象，根据治疗方法分为观察组和对照组，每组27例。观察组患者给予地西他滨和三氧化二砷联合治疗，对照组患者给予高三尖杉酯碱和盐酸阿糖胞苷联合治疗；2组患者分别于治疗前及治疗2个周期后检测白细胞计数（WBC）、红细胞计数（RBC）、血小板计数（BPC）及血红蛋白（HGB）水平，并对2组患者的临床疗效及不良反应发生率进行比较。 结果　观察组患者完全缓解17例，部分缓解6例，未缓解3例，总有效率为85.19%（23/27）；对照组患者完全缓解14例，部分缓解10例，未缓解3例，总有效率为88.89%（24/27），2组患者总有效率比较差异无统计学意义（χ2=1.351，P>0.05）。治疗前2组患者WBC、RBC、BPC及HGB水平比较差异均无统计学意义（P>0.05）。对照组患者治疗后WBC、BPC及HGB水平显著高于治疗前（P<0.05），但对照组患者治疗前后RBC比较差异无统计学意义（P>0.05）；观察组患者治疗后WBC、RBC、BPC及HGB水平显著高于治疗前（P<0.05）。治疗后，观察组患者WBC、RBC、BPC及HGB水平显著高于对照组（P<0.05）。观察组患者中性粒细胞减少、严重感染、严重出血及胃肠道反应发生率分别为33.33%（9/27）、25.93%（7/27）、14.81%（4/27）、7.41%（2/27），对照组患者中性粒细胞减少、严重感染、严重出血及胃肠道反应发生率分别为100.00%（27/27）、74.07%（20/27）、70.37%（19/27）、100.00%（27/27）；观察组患者中性粒细胞减少、严重感染、严重出血及胃肠道反应发生率显著低于对照组（χ2=5.035、7.619、7.932、7.881，P<0.05）。结论　地西他滨联合三氧化二砷治疗老年急性髓系白血病（非急性早幼粒细胞白血病）疗效肯定，且不良反应发生率低，安全性较好。
Abstract:
Objective　To investigate the clinical effect and safety of decitabine combined with arsenic trioxide in the treatment of senile acute myeloid leukemia (non-acute promyelocytic leukemia).Methods　A total of 54 elderly patients with acute myeloid leukemia admitted to Xinxiang Central Hospital from February 2016 to October 2018 were selected as the study objects.They were divided into observation group and control group according to the treatment methods，with 27 cases in each group.The patients in the observation group were treated with decitabine and arsenic trioxide，while the patients in the control group were treated with homoharringtonine and cytarabine hydrochloride.The white blood cell count (WBC)，red blood cell count (RBC)，platelet count (BPC) and hemoglobin (HGB) level of patients in the two groups were detected before treatment and after two cycles of treatment.The clinical effect and the incidence of adverse reactions were compared between the two groups.Results　In the observation group，there were 17 cases of complete remission，6 cases of partial remission and 3 cases of non remission，the total effective rate was 85.19% (23/27).In the control group，there were 14 cases of complete remission，10 cases of partial remission and 3 cases of non remission，the total effective rate was 88.89% (24/27).There was no significant difference in the total effective rate between the two groups (χ2=1.351，P>0.05).There was no significant difference in WBC，RBC，BPC and HGB levels between the two groups before treatment (P>0.05).The WBC，BPC and HGB levels after treatment were significantly higher than those before treatment in the control group (P<0.05);there was no significant difference in RBC before and after treatment in the control group (P>0.05).The WBC，RBC，BPC and HGB levels after treatment were significantly higher than those before treatment in the observation group (P<0.05).After treatment，the WBC，RBC，BPC and HGB levels in the observation group were significantly higher than those in the control group (P<0.05).The incidence of neutropenia，severe infection，severe bleeding and gastrointestinal reaction in the observation group was 33.33% (9/27)，25.93% (7/27)，14.81% (4/27) and 7.41% (2/27)，respectively;the incidence of neutropenia，severe infection，severe bleeding and gastrointestinal reaction in the control group was 100.00% (27/27)，74.07% (20/27)，70.37% (19/27) and 100.00% (27/27)，respectively.The incidences of neutropenia，severe infection，severe bleeding and gastrointestinal reaction in the observation group were significantly lower than those in the control group (χ2=5.035，7.619，7.932，7.881; P<0.05).Conclusion　Decitabine combined with arsenic trioxide in the treatment of senile acute myeloid leukemia (non-acute promyelocytic leukemia) is effective，and the incidence of adverse reactions is low and the safety is good.

参考文献/References:

［1］　KLEPIN H D，RAO A V，PARDEE T S.Acute myeloid leukemia and myelodysplastic syndromes in older adults［J］.J Clin Oncol,2014，32(24): 2541-2552.
［2］　LINDSLEY R C，MAR B G，MAZZOLA E，et al.Acute myeloid leukemia ontogeny is defined by distinct somatic mutations［J］.Blood,2015,125(9): 1367-1376.
［3］　CREUTZIG U，ZIMMERMANN M，REINHARDT D，et al.Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups［J］.Cancer,2016,122(24): 3821-3830.
［4］　GORE S D，GOJO I，SEKERES M A，et al.Single cycle of arsenic trioxidebased consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia［J］.J Clin Oncol,2010,28(6):1047-1053.
［5］　ARBER D A，ORAZI A，HASSERJIAN R，et al.The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia［ J］.Blood，2016，127(20): 2391-2405.
［6］　沈悌,赵永强.血液病诊断及疗效标准［M］.4版.北京：科学出版社，2018：203.
［7］　申清云，高大.老年急性髓系白血病的治疗方法研究进展［J］.新乡医学院学报，2019，36（1）：96-100.
［8］　KONOPLEVA M，POLLYEA D A，POTLURI J，et al.Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia［J］.Cancer Discov,2016,6(10): 1106-1117.
［9］　DINARDO C D，PRATZ K W，LETAI A，et al.Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised，open-label，phase 1b study［J］.Lancet Oncol,2018,19(2):216-228.
［10］　AU W Y，CHEUNG G T，YUEN T W，et al.Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide［J］.Arch Intern Med，2005,165(9):1067-1068.
［11］　AU W Y，FONG B M，TAM S，et al.Feasibility of oral arsenic trioxide treatment for acute promyelocytic leukemia during hemodialysis［J］.Ann Hematol,2013,92(3):417-418.
［12］　AU W Y，LIU C L，TAM S，et al.Oral arsenic trioxide therapy for acute promyelocytic leukemia before and after liver transplantation for hepatitis B virus-related liver failure［J］.Ann Hematol,2007,86(10):771-772.
［13］　LO-COCO F，CICCONI L.Outpatient oral treatment for acute promyelocytic leukemia［J］.N Engl J Med,2015,372(9):884-885.

相似文献/References:

[1]张婧婧,张楠,王侠,等.急性髓系白血病四色流式细胞术免疫学分型特点分析[J].新乡医学院学报,2011,28(03):323.
[2]崔珊珊,李雅慧,赵晨瑾,等.二甲双胍对人急性髓系白血病KG1a细胞增殖和凋亡的影响及其机制[J].新乡医学院学报,2021,38(10):901.[doi:10.7683/xxyxyxb.2021.10.001]
　CUI Shanshan,LI Yahui,ZHAO Chenjin,et al.Effect and mechanism of metformin on proliferation and apoptosis of human acute myeloid leukemia KG1a cells[J].Journal of Xinxiang Medical University,2021,38(12):901.[doi:10.7683/xxyxyxb.2021.10.001]
[3]赵小强,吴雅莉,仝佳音,等.鱼藤素对急性髓系白血病KG-1a细胞增殖和凋亡的影响及机制[J].新乡医学院学报,2021,38(12):1121.[doi:10.7683/xxyxyxb.2021.12.003]
　ZHAO Xiaoqiang,WU Yali,TONG Jiayin,et al.Effect of deguelin on the proliferation and apoptosis of acute myeloid leukemia KG-1a cells and its mechanism[J].Journal of Xinxiang Medical University,2021,38(12):1121.[doi:10.7683/xxyxyxb.2021.12.003]
[4]申清云,高　大.老年急性髓系白血病的治疗方法研究进展[J].新乡医学院学报,2019,36(1):096.[doi:10.7683/xxyxyxb.2019.01.022]
[5]王继芳,魏秀丽.氟达拉滨联合阿糖胞苷治疗急性髓系白血病疗效观察[J].新乡医学院学报,2018,35(3):204.[doi:10.7683/xxyxyxb.2018.03.011]
　WANG Ji-fang,WEI Xiu-li.Effect of fludarabine combined with cytarabine on acute myeloid leukemia[J].Journal of Xinxiang Medical University,2018,35(12):204.[doi:10.7683/xxyxyxb.2018.03.011]
[6]尹俊杰,梁　波,王继芳,等.阿柔比星为基础的联合化学治疗方案治疗成人初治急性髓系白血病疗效观察[J].新乡医学院学报,2017,34(1):072.[doi:10.7683/xxyxyxb.2017.01.021]
　YIN Jun-jie,LIANG Bo,WANG Ji-fang,et al.Efficacy of aclarubicin-based chemotherapy induction regimens for adult de-novo acute myeloid leukemia[J].Journal of Xinxiang Medical University,2017,34(12):072.[doi:10.7683/xxyxyxb.2017.01.021]
[7]孟君霞,武永强,唐　广,等.CD7抗原表达与急性髓系白血病临床特征、细胞遗传学特点及预后的关系[J].新乡医学院学报,2016,33(6):508.[doi:10.7683/xxyxyxb.2016.06.017]
　MENG Jun-xia,WU Yong-qiang,TANG Guang,et al.Relationship between CD7 antigen expression and clinical features，cytogenetic features，prognosis of acute myeloid leukemia[J].Journal of Xinxiang Medical University,2016,33(12):508.[doi:10.7683/xxyxyxb.2016.06.017]
[8]张晓冬,林晓媛.急性髓系白血病患者外周血调节性T细胞、辅助性T细胞17及其相关细胞因子的表达及意义[J].新乡医学院学报,2023,40(4):339.[doi:10.7683/xxyxyxb.2023.04.008]
　ZHANG Xiaodong,LIN Xiaoyuan.Expression and significance of regulatory T cells,helper T cell 17 cells and their related cytokines in peripheral blood of patients with acute myeloid leukemia[J].Journal of Xinxiang Medical University,2023,40(12):339.[doi:10.7683/xxyxyxb.2023.04.008]
[9]张彦平,刘蒙蒙,展新荣.地西他滨联合小剂量高三尖杉酯碱和阿糖胞苷治疗老年急性髓系白血病疗效观察[J].新乡医学院学报,2020,37(11):1068.[doi:10.7683/xxyxyxb.2020.11.014]
　ZHANG Yanping,LIU Mengmeng,ZHAN Xinrong.Effect of decitabine combined with low-dose homoharringtonine and cytarabine in the treatment of elderly patients with acute myeloid leukemia[J].Journal of Xinxiang Medical University,2020,37(12):1068.[doi:10.7683/xxyxyxb.2020.11.014]

更新日期/Last Update: 2019-12-05